$IDRA,,,Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares are trading up 13% to $1.96 in the after-hours session following its announcement that the FDA has granted orphan drug designation for IMO-2125 for the treatment of melanoma. While the news is hardly ground-breaking, overall bullish sentiment in the sector over the last week has no doubt played a part in the move.